1. [A Case of HER2-Positive Esophagogastric Junction Cancer with Perforation Curatively Resected after Neoadjuvant Chemotherapy plus Trastuzumab].
- Author
-
Toshima H, Hisamatsu A, Shimada K, Saito M, Suzuki M, Matsukawa M, and Inoue H
- Subjects
- Cisplatin administration & dosage, Drug Combinations, Humans, Male, Oxonic Acid administration & dosage, Receptor, ErbB-2 analysis, Stomach Diseases etiology, Stomach Neoplasms complications, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Tegafur administration & dosage, Trastuzumab administration & dosage, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Esophagogastric Junction pathology, Neoadjuvant Therapy, Stomach Diseases surgery, Stomach Neoplasms drug therapy
- Abstract
A 60-year-old man was diagnosed with adenocarcinoma of the esophagogastric junction with lymph node metastasis along the left gastric artery. The clinical stage was determined to be T4b, N1, M0, Stage IIIB, and a neoadjuvant chemotherapy (NAC)regimen of capecitabine/CDDP plus trastuzumab was selected for treatment. Before 3 courses of chemotherapy, the patient developed perforated gastric cancer. With conservative therapy, we were able to obtain closure of the perforation without affecting the curability of the cancer. We changed the chemotherapy regimen to S-1/CDDP plus trastuzumab, and the patient underwent curative resection.
- Published
- 2016